Table 4. NRAS61 and HRAS61mutation analysis.

Group	Case	N-RAS	H-RAS
Benign samples (Supplementary Table S1)	1	WT	WT
	2	WT	WT
	3	WT	WT
	4	WT	WT
	5	WT	WT
	6	WT	WT
	7	WT	WT
	8	WT	WT
	9	WT	WT
	10	WT	WT
	11	WT	WT
	12	WT	WT
	13	Ala59Pro (c.175G>C)	WT
	14	WT	WT
	15	WT	WT
	16	WT	WT
	17	WT	WT
	18	WT	WT
	19	WT	WT
	20	WT	WT
	21	WT	WT
	22	WT	WT
FTC samples (Supplementary Table S2)	1V,C	WT	WT
	2O,V,C	WT	WT
	3O,C	WT	WT
	4O,V,C	WT	WT
	5V,C	WT	WT
	6C	WT	WT
	7V,C	Gln61Arg (c.182A>G)	WT
	8V,C	WT	WT
	9C	WT	WT
	10C	WT	WT
	11O,V	WT	WT
	12V	WT	WT
	13V	WT	WT
	14C	WT	WT
	15O,V,C	WT	WT
	16C	WT	WT
	17C	WT	WT
	18V	WT	WT
	19C	WT	WT
	20V,C	WT	WT
FTC samples (Supplementary Table 2)	21V	WT	WT
	22V	WT	WT
	23V	WT	WT
	24O,C	WT	WT
	25O,C	WT	WT
	26V	WT	WT
	27O,C	WT	WT
	28O,V,C	WT	WT
	29O,C	Gln61Arg (c.182A>G)	WT
	30O,V,C	WT	WT
	31O,V,C	WT	Gln61Arg (c.182A>G)
	32O,C	WT	WT
	33O,V,C	WT	WT
	34O,V,C	WT	WT
	35O,V,C	WT	WT
	36O,C	WT	WT
	37O,C	WT	WT
	38O,C	WT	WT
	39O,V,C	WT	WT
	40V	WT	WT
	41C	WT	WT
	42C	WT	WT
	43V,C	Gln61Arg (c.182A>G)	WT
	44V,C	WT	WT
	45C	WT	WT
	46C	WT	WT
	47C	Gln61Arg (c.182A>G)	WT
	48C	WT	WT
	49C	WT	WT
	50O,C	WT	WT
	51O,V,C	WT	WT
	52V,C	WT	WT
	53O,C	Gln61Arg (c.182A>G)	WT
	54O,V,C	WT	WT
	55V	WT	WT
	56V	WT	WT

^O– oncocytic

^V– vascular invasion

^C– capsular invasion